Cardiometabolic diseases — including type 2 diabetes, obesity, steatotic liver disease, and cardiovascular disease — are among the greatest health challenges of our time and remain leading causes of death worldwide. Despite major advances in prevention, diagnosis, and treatment, much work remains to better understand the biological mechanisms that drive these conditions and to translate that knowledge into more precise and effective interventions.

Over the past decade, research has shown that the gut microbiome may play a significant role in cardiometabolic health. Investigators have moved beyond describing differences in microbial composition to uncovering functional pathways, microbial metabolites, and host–microbe interactions that may influence disease development and progression.

While microbiome research has generated compelling biological insights, translating these discoveries into clear causal evidence in people has proven challenging. Cardiometabolic diseases are highly complex and vary among individuals, intervention outcomes have often been variable or inconsistent, and study designs have not always been sufficiently aligned around endpoints, patient selection or mechanistic validation. As a result, an important gap remains between scientific discovery and clinical application.

Addressing this gap represents a major opportunity for progress. It requires iterative validation across models, mechanisms and patient populations to determine which microbial functions are protective, which contribute to disease, and how they can be safely and effectively targeted.

The Microbiome Health Initiative is positioned to help lead this next phase of the field. Our centre brings together established global leaders and a carefully selected group of next-generation Danish researchers, creating a dynamic environment that combines scientific excellence with forward-looking innovation.

Our strategy is built around two fundamental pillars:

• Establishing proof of concept through intervention studies in people, 
• Generating in-depth mechanistic understanding through translational research. 

Together, these pillars allow us to connect biological insight with clinical relevance and identify microbiome-based approaches that may improve health outcomes for people living with, or at risk of developing, cardiometabolic disease. 

Working across disciplines, the Microbiome Health Initiative (MHI) connects data, models, microbial strains, metabolites and mechanistic insight in a continuous translational pipeline. From omics analysis and microbiome modelling, through microbial cultivation, formulation and controlled mechanistic testing, to animal models and ultimately human studies, our approach is designed to bridge the gap between discovery and application.

By aligning expertise across microbiology, metabolism, clinical research and therapeutic development, MHI seeks to generate evidence that can guide the next generation of microbiome-informed interventions.

Add: Investigate beneficial bacteria and metabolites that may help protect against cardiometabolic disease or improve health outcomes.

Remove: Study harmful microbial or enzymatic activities that contribute to disease by producing damaging metabolites. 

Regulate: Modulate these processes through therapeutic or dietary interventions. 

Our work connects data, models, microbial strains, metabolites and mechanistic insight in a continuous translational pipeline. This pipeline extends from omics analysis and microbiome modelling, through microbial cultivation, formulation and controlled mechanistic testing, to animal models and ultimately human studies.